Clinical trial
A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.
NCT01684410 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.
- Lead sponsor
- Grifols Therapeutics LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2012
- Completion date
- October 31, 2013
- Enrollment
- 30 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.